Author: Editor

Andrew Cowan, MD Assistant Professor, Hematology/Oncology, University of Washington School of Medicine @SeattleCCA differentiates between various anti-CD-38 monoclonal antibodies and elaborates on the role of isatuximab in the management of multiple myeloma

Andrew Cowan, MD Assistant Professor, Hematology/Oncology, University of Washington School of Medicine @SeattleCCA discusses the promising data on multiple myeloma data presented at ASH 2019.

Andrew Cowan, MD Assistant Professor, Hematology/Oncology, University of Washington School of Medicine @SeattleCCA discusses the role of CAR-T cell therapy in multiple myeloma.

Andrew Cowan, MD Assistant Professor, Hematology/Oncology, University of Washington School of Medicine @SeattleCCA discusses the role of human BCMA CAR-T cells in the management of multiple myeloma.

Luciano J. Costa, MD, PhD @End_myeloma @uabmedicine Associate Professor of Medicine, Blood and Marrow Transplantation and Cell Therapy, O’Neal Comprehensive Cancer Center, University of Alabama at Birmingham, explains how academic and community oncologists can order a minimal residual disease (MRD) test.

Luciano J. Costa, MD, PhD @End_myeloma @uabmedicine Associate Professor of Medicine, Blood and Marrow Transplantation and Cell Therapy, O’Neal Comprehensive Cancer Center, University of Alabama at Birmingham, provides opinion on whether minimal residual disease (MRD) tests can be used to help guide treatment decisions.

Luciano J. Costa, MD, PhD @End_myeloma @uabmedicine Associate Professor of Medicine, Blood and Marrow Transplantation and Cell Therapy, O’Neal Comprehensive Cancer Center, University of Alabama at Birmingham discusses how MRD can be used as a predictor of outcome.

Luciano J. Costa, MD, PhD @End_myeloma @uabmedicine Associate Professor of Medicine, Blood and Marrow Transplantation and Cell Therapy, O’Neal Comprehensive Cancer Center, University of Alabama at Birmingham explains how measurement of minimal residual disease (MRD) is evolving as an endpoint in clinical trials.

John Burke, MD Physician, Associate Chair, US Oncology Hematology Research Program, Medical Oncology/ Hematology, Rocky Mountain Cancer Centers discusses the design and objectives of the Phase Ib study assessing safety and preliminary efficacy of tafasitamab or tafasitamab plus lenalidomide in addition to R-CHOP in patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL).

John Burke, MD Physician, Associate Chair, US Oncology Hematology Research Program, Medical Oncology/ Hematology, Rocky Mountain Cancer Centers outlines the patient profile that is best suited for zanubrutinib in relapsed or refractory mantle cell lymphoma (MCL)

John Burke, MD Physician, Associate Chair, US Oncology Hematology Research Program, Medical Oncology/ Hematology, Rocky Mountain Cancer Centers discusses how physicians should be thinking about the use of BTK inhibitors in the treatment of CLL.

Noa Biran, MD @HackensackUMC Oncology Specialist, Division of Multiple Myeloma, John Theurer Cancer Center, Part of Hackensack University Medical Center, discusses the role of BCMA CAR-T cells in the management of multiple myeloma.

Noa Biran, MD @HackensackUMC Oncology Specialist, Division of Multiple Myeloma, John Theurer Cancer Center, Part of Hackensack University Medical Center, provides information on the phase 3 ICARIA-MM study.

Noa Biran, MD @HackensackUMC Oncology Specialist, Division of Multiple Myeloma, John Theurer Cancer Center, Part of Hackensack University Medical Center, explains the difference in JNJ-4528 from other CAR-T cell products.

Noa Biran, MD @HackensackUMC Oncology Specialist, Division of Multiple Myeloma, John Theurer Cancer Center, Part of Hackensack University Medical Center, discusses the outcomes of the CARTITUDE-1 study investigating JNJ-4528 directed against BCMA in relapsed/refractory multiple myeloma

Saro Armenian, DO, MPH @cityofhope Pediatric Hematologist/Oncologist, Associate Professor, Departments of Pediatrics and Population Sciences, City of Hope Helford Clinical Research Hospital discusses the long term survivors of AML bone marrow transplant implications.

Saro Armenian, DO, MPH @cityofhope Pediatric Hematologist/Oncologist, Associate Professor, Departments of Pediatrics and Population Sciences, City of Hope Helford Clinical Research Hospital discusses immunotherapy changing the landscape of hematologic cancers.

Saro Armenian, DO, MPH @cityofhope Pediatric Hematologist/Oncologist, Associate Professor, Departments of Pediatrics and Population Sciences, City of Hope Helford Clinical Research Hospital discusses the most promising clinical innovations in the treatment of hematologic cancers.

David Andorsky, MD Medical Oncologist, Associate Chair, US Oncology Research Group, Rocky Mountain Cancer Centers shares the implications of real-world evidence for oncologists.

David Andorsky, MD Medical Oncologist, Associate Chair, US Oncology Research Group, Rocky Mountain Cancer Centers shares the results and findings for idelalisib in patients with relapsed or refractory follicular lymphoma.

David Andorsky, MD Medical Oncologist, Associate Chair, US Oncology Research Group, Rocky Mountain Cancer Centers discusses how RWE (real-world evidence) has impacted the oncology community.

David Andorsky, MD Medical Oncologist, Associate Chair, US Oncology Research Group, Rocky Mountain Cancer Centers discusses how RWE (real-world evidence) compliments clinical trial results.

Joseph Alvarnas, MD @cityofhope Vice President of Government Affairs, Senior Medical Director for Employer Strategy, Director of Value Based Analytics, City of Hope on seeking new solutions for providing proper access to innovative therapy.

Joseph Alvarnas, MD @cityofhope Vice President of Government Affairs, Senior Medical Director for Employer Strategy, Director of Value Based Analytics, City of Hope discusses the challenges cancer centers face when delivering innovative therapies.

Joseph Alvarnas, MD @cityofhope Vice President of Government Affairs, Senior Medical Director for Employer Strategy, Director of Value Based Analytics, City of Hope explains his philosophy regarding CAR-T cell therapy value to the care of patients.

Joseph Alvarnas, MD @cityofhope Vice President of Government Affairs, Senior Medical Director for Employer Strategy, Director of Value Based Analytics, City of Hope discusses how to integrate clinical innovations into treatment algorithms in multidisciplinary teams.

Briggs Morrison, MD Chief Executive Officer of @Syndax discusses important details to note in this study. ___________ Syndax Pharmaceuticals, Inc. (“Syndax,” the “Company” or “we”) (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Science magazine has published a preclinical report supporting the potential role of MLL1-Menin inhibition in the management of nucleophosmin (NPM1) mutant acute myeloid leukemia (AML). The article, “Therapeutic targeting of preleukemia cells in a mouse model of NPM1 mutant acute myeloid leukemia,” will be published in the journal’s January 31, 2020 issue and is currently available online. This study examined the activity of…

National Comprehensive Cancer Network to address HPV-related cancer prevention and treatment with World Cancer Day fundraiser and at upcoming NCCN 2020 Annual Conference. Learn more at NCCN.org/wcd and join the conversation online with hashtags #WorldCancerDay, #IAmAndIWill, and #NCCNGlobal.  — February 4, 2020, marks the 20th annual World Cancer Day. On this day, the National Comprehensive Cancer Network® (NCCN®)—a nonprofit alliance of leading cancer centers—is commemorating its 25th anniversary year by looking back at the tremendous progress made against cancer over the past quarter-century and looking forward to further define and advance high-quality, high-value, patient-centered cancer care globally. Earlier this year, the American Cancer Society (ACS) announced that the cancer death…

United Therapeutics Corporation (Nasdaq: UTHR) today announced topline results from the phase 2/3 DISTINCT clinical study evaluating Unituxin® (dinutuximab) Injection added to irinotecan compared to irinotecan or topotecan alone in patients with relapsed or refractory small cell lung cancer (SCLC). The DISTINCT trial did not meet its primary efficacy objective of extending the overall survival with Unituxin and irinotecan versus using irinotecan alone. The safety profile of dinutuximab in DISTINCT was consistent with prior studies and the current Unituxin product label. Full data from the DISTINCT study will be made available through scientific disclosure at upcoming conferences and in peer-reviewed publications.   “We thank the principal investigators, patients and…

Briggs Morrison, MD Chief Executive Officer of @Syndax answers how likely is this to translate into being beneficial for patients and more common questions about NMP1 AML. ___________ Syndax Pharmaceuticals, Inc. (“Syndax,” the “Company” or “we”) (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Science magazine has published a preclinical report supporting the potential role of MLL1-Menin inhibition in the management of nucleophosmin (NPM1) mutant acute myeloid leukemia (AML). The article, “Therapeutic targeting of preleukemia cells in a mouse model of NPM1 mutant acute myeloid leukemia,” will be published in the journal’s January 31,…

Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced that its open label, single arm US Phase 1 trial met its primary objective of demonstrating the safety of Liposomal Annamycin (“Annamycin”) in treating relapsed or refractory acute myeloid leukemia (“AML”). The Company also announced an update on interim enrollment, safety and efficacy data in its parallel Phase 1 trial in Europe, which continues with dose escalation, thus far without safety concerns. Safety of Annamycin in AML Patients The US Phase 1 trial met its…

Briggs Morrison, MD Chief Executive Officer of @Syndax discusses a preclinical study on the activity of menin-MLL inhibition for the treatment of NPM1 in AML. ___________ Syndax Pharmaceuticals, Inc. (“Syndax,” the “Company” or “we”) (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Science magazine has published a preclinical report supporting the potential role of MLL1-Menin inhibition in the management of nucleophosmin (NPM1) mutant acute myeloid leukemia (AML). The article, “Therapeutic targeting of preleukemia cells in a mouse model of NPM1 mutant acute myeloid leukemia,” will be published in the journal’s January 31, 2020 issue…

– If approved by the European Commission (EC), VENCLYXTO® plus obinutuzumab would be the first chemotherapy-free, combination regimen given with a fixed duration for patients with previously untreated chronic lymphocytic leukemia (CLL) – Represents third positive CHMP opinion for VENCLYXTO; further supports the growing utility of the therapy across multiple lines of CLL Positive opinion based on data from Phase 3 CLL14 trial, which showed that patients who completed one year of treatment with VENCLYXTO plus obinutuzumab had prolonged progression-free survival and higher rates of minimal residual disease negativity compared to patients receiving a standard of care chemoimmunotherapy regimen of…

Cleveland Clinic researchers have identified for the first time an explanation of why patients with identical PTEN mutations often have vastly different clinical presentations. In a new study published in JAMA Network Open, a team of researchers led by Charis Eng, MD, PhD, of Cleveland Clinic Lerner Research Institute’s Genomic Medicine Institute, discovered that copy number variations (CNVs) may act as genomic modifiers that influence the risk of autism spectrum disorder (ASD) and/or developmental delay (DD) versus cancer risk in individuals with PTEN mutations.   Germline mutations of the tumor suppressor gene PTEN are associated with a group of genetic disorders that increase the risk of certain cancers, cognitive and…

Daniel Hayes, MD @hoosierdfh of University of Michigan @UMich answers commonly asked questions in pharmacogenomics and endocrine therapy in breast cancer.

– Application Supported by Results of Pivotal HER2CLIMB Trial -  – First Investigational Therapy in a Pivotal Trial to Include Patients with Metastatic HER2-Positive Breast Cancer with Active Brain Metastases -    EU Marketing Authorization Application (MAA) Follows Recent Submission of Tucatinib New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) – Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that the European Medicines Agency (EMA) validated the Marketing Authorization Application (MAA) for tucatinib, in combination with trastuzumab and capecitabine, for the treatment of adult patients with locally advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain…

Daniel Hayes, MD @hoosierdfh of University of Michigan @UMich discusses endocrine therapy in breast cancer.

Results support ongoing Phase 1/2 AUGMENT-101 trial of Syndax Pharmaceuticals’ lead Menin-MLL inhibitor, SNDX-5613, for the treatment of adults with relapsed/refractory acute leukemias, including NPM1 mutant AML – Syndax Pharmaceuticals, Inc. (“Syndax,” the “Company” or “we”) (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Science magazine has published a preclinical report supporting the potential role of MLL1-Menin inhibition in the management of nucleophosmin (NPM1) mutant acute myeloid leukemia (AML). The article, “Therapeutic targeting of preleukemia cells in a mouse model of NPM1 mutant acute myeloid leukemia,” will be published in the journal’s January 31,…

Using genetically engineered human pluripotent stem cells, University of California San Diego School of Medicine researchers created a new type of cancer model to study in vivo how glioblastoma, the most common and aggressive form of brain cancer, develops and changes over time.   “We have developed stem cell models that are CRISPR-engineered to have tumor-associated driver mutations in glioblastoma, which harbor essentially all features of patient-derived tumors, including extrachromosomal DNA amplification,” said co-senior author Frank B. Funari, PhD, professor in the Department of Pathology at UC San Diego School of Medicine and head of the Laboratory of Tumor Biology in the…

Gerardo Antonio Umanzor, MD of Liga Contra el Cáncer explains getting results down in oral paclitaxel: a Phase III clinical study in metastatic breast cancer.

Gerardo Antonio Umanzor, MD of Liga Contra el Cáncer answers frequently asked questions on paclitaxel shown to be superior to IV paclitaxel: a Phase III clinical study in metastatic breast cancer.

Gerardo Antonio Umanzor, MD of Liga Contra el Cáncer on paclitaxel shown to be superior to IV paclitaxel on confirmed response and survival with less neuropathy: a Phase III clinical study in metastatic breast cancer.

First patient with metastatic triple-negative breast cancer (mTNBC) continues to show no detectable circulating tumor cells (CTC) or putative metastatic tumor cells after 15 weeks of treatment with leronlimab in combination with carboplatin Second patient with stage 4 HER2+ metastatic breast cancer (MBC) shows 50 percent shrinkage in the primary tumor and no new signs of metastasis in the brain after treatment with leronlimab as a monotherapy CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today additional promising results from its…

– Improved clinical outcomes in advanced gastric/gastroesophageal junction cancer patients with DKK1-high tumors when treated with DKN-01 and anti PD-1 therapy – Tumoral DKK1 levels will be used to prospectively identify patients in subsequent studies in new collaboration with BeiGene Radiomic imaging analysis has identified a potentially useful biomarker to non-invasively evaluate DKK1 expression Leap Therapeutics, Inc. (Nasdaq: LPTX) today presented updated clinical data from its recently completed Phase 1/2 clinical trial of DKN-01 in patients with advanced or recurrent esophagogastric cancer (EGC) at the 2020 ASCO GI annual meeting. Updated response and survival data in the anti-PD-1/PD-L1 naïve gastric/gastroesophageal…

Philadelphia, PA (January 27, 2020) – Oncoceutics announced that the National Brain Tumor Society (NBTS) has committed to providing more than $200,000 in funding, with the potential for multiple years, to support a Phase II clinical trial of ONC201, the first imipridone dopamine receptor D2 antagonist (DRD2), in a molecular subset of high grade gliomas. The future clinical trial will evaluate the efficacy of single agent ONC201 in patients who have a recurrent form of high-grade glioma that exhibits low expression of epidermal growth factor receptor (EGFR), which is associated with elevated DRD2 expression and ONC201 sensitivity. The trial will…

Today, the American Society of Hematology (ASH) released new clinical practice guidelines on Sickle Cell Disease (SCD)-Related Transfusion Support. These guidelines are part of a series of five guidelines ASH is developing on SCD to provide updated treatment guidelines that reflect the newest evidence about the disease, ensuring the medical community can better treat SCD and people with SCD can make the best decisions for their care. The guidelines published in the Society’s peer-reviewed journal Blood Advances. Three more chapters are in development. ASH previously published SCD-Related Cardiopulmonary and Kidney Disease Guidelines in December 2019. “It is an incredibly exciting time with nearly limitless potential…

GRACE is very excited to bring to you our new program, Supportive Care in Cancer Treatment.Arjun Gupta, MD is the host of this video series, Supportive Care in Cancer Treatment. In this video Dr. Gupta speaks with his guest, Lysa Buonanno, who is a lung cancer patient and patient advocate.Lysa and Dr. Gupta discuss the often poorly understood subject of ‘chemobrain’, or attention, thinking or memory problems in patients with cancer.To join the conversation, visit https://cancergrace.org/forum.To find additional CancerGRACE resources, visit https://cancergrace.org.To donate to CancerGRACE, visit https://cancergrace.org/donate.

  First Surveillance Tests Designed to Enable Community Hospitals and Labs to Deliver Rapid, Accurate and Actionable Genomic Information to Oncology Physicians and Patients Across Care Settings ArcherDX, Inc., today announced it has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for its Personalized Cancer Monitoring (PCM) technology, a bespoke, minimally-invasive and highly-sensitive product intended for early-stage cancer treatment monitoring and recurrence surveillance. ArcherDX’s technology enables healthcare providers across community and academic care settings access to genomic information in their laboratory, saving critical time and allowing world-class, cost-effective care locally. The goal of the Breakthrough Devices…

Meletios Athanasios Dimopoulos @thanosdimop of University Athens School of Medicine discusses what’s next in research for the TOUMRALINE-MM4 study. _________ Read here: https://www.takeda.com/newsroom/newsreleases/2019/phase-3-trial-of-ninlaro-ixazomib-as-first-line-maintenance-therapy-met-primary-endpoint-in-multiple-myeloma-patients-not-treated-with-stem-cell-transplantation/

Meletios Athanasios Dimopoulos @thanosdimop of University Athens School of Medicine discusses safety concerns regarding the trial. _________ Read here: https://www.takeda.com/newsroom/newsreleases/2019/phase-3-trial-of-ninlaro-ixazomib-as-first-line-maintenance-therapy-met-primary-endpoint-in-multiple-myeloma-patients-not-treated-with-stem-cell-transplantation/  

The American Society of Hematology (ASH) is pleased to announce that Gabriela Hobbs, MD, of Massachusetts General Hospital, and Oluwatoyosi Onwuemene, MD, MS, of Duke University have been selected to participate in the American Society of Hematology-Harold Amos Medical Faculty Development Program (ASH-AMFDP), a partnership between ASH and the Robert Wood Johnson Foundation (RWJF). The program, designed to increase the number of underrepresented minority scholars in the field of hematology with academic and research appointments, provides four-year research awards, totaling $420,000. Drs. Hobbs and Onwuemene will spend at least 70% of their research time under the mentorship of a senior…

Isabel Arrillaga-Romany, MD, PhD of @MGHNeuroOnc @Oncoceutics explains how this is going to affect clinicians today and what clinicians should know about patients with the H3 K27 mutation. ________ Oncoceutics, Inc. announced that results from the second and third cohort of the Phase II trial for patients with recurrent glioblastoma treated with the company’s lead imipridone, ONC201, were recently published in the journal Neuro-Oncology. This manuscript represents the third publication among a series of reports demonstrating durable radiographic regressions with ONC201 in patients with H3 K27M-mutant glioma. The study (NCT02525692) also demonstrated that weekly oral administration of ONC201 given as a single agent was well-tolerated, achieved therapeutic…

Meletios Athanasios Dimopoulos @thanosdimop of University Athens School of Medicine discusses whether they will be submitting to the FDA or not.

Isabel Arrillaga-Romany, MD, PhD of @MGHNeuroOnc @Oncoceutics answers what data has come out of the trial? _________ Oncoceutics, Inc. announced that results from the second and third cohort of the Phase II trial for patients with recurrent glioblastoma treated with the company’s lead imipridone, ONC201, were recently published in the journal Neuro-Oncology. This manuscript represents the third publication among a series of reports demonstrating durable radiographic regressions with ONC201 in patients with H3 K27M-mutant glioma. The study (NCT02525692) also demonstrated that weekly oral administration of ONC201 given as a single agent was well-tolerated, achieved therapeutic intratumoral concentrations, and intratumoral pharmacodynamic activity in adult recurrent glioblastoma patients. ONC201 achieved…

Meletios Athanasios Dimopoulos @thanosdimop of University Athens School of Medicine answers why ninlaro was compared to a placebo in TOURMALINE-MM4. Dr. Dimopoulous further discusses when the TOURMALINE-MM4 trial results will be presented.

Isabel Arrillaga-Romany, MD, PhD of @MGHNeuroOnc @Oncoceutics answers how can we get access to this drug for glioblastoma? ___________ Oncoceutics, Inc. announced that results from the second and third cohort of the Phase II trial for patients with recurrent glioblastoma treated with the company’s lead imipridone, ONC201, were recently published in the journal Neuro-Oncology. This manuscript represents the third publication among a series of reports demonstrating durable radiographic regressions with ONC201 in patients with H3 K27M-mutant glioma. The study (NCT02525692) also demonstrated that weekly oral administration of ONC201 given as a single agent was well-tolerated, achieved therapeutic intratumoral concentrations, and intratumoral pharmacodynamic activity in adult recurrent glioblastoma…

Meletios Athanasios Dimopoulos @thanosdimop of University Athens School of Medicine discusses the design of the TOURMALINE-MM4 study and answers if the trail met its primary endpoint.

Meletios Athanasios Dimopoulos @thanosdimop of University Athens School of Medicine discusses the phase 3 trial of ninlaro as first line maintenance therapy in multiple myeloma patients.

Isabel Arrillaga-Romany, MD, PhD of @MGHNeuroOnc @Oncoceutics discusses what’s next in ONC201 in adult recurrent glioblastoma. __________ Oncoceutics, Inc. announced that results from the second and third cohort of the Phase II trial for patients with recurrent glioblastoma treated with the company’s lead imipridone, ONC201, were recently published in the journal Neuro-Oncology. This manuscript represents the third publication among a series of reports demonstrating durable radiographic regressions with ONC201 in patients with H3 K27M-mutant glioma. The study (NCT02525692) also demonstrated that weekly oral administration of ONC201 given as a single agent was well-tolerated, achieved therapeutic intratumoral concentrations, and intratumoral pharmacodynamic activity in adult recurrent glioblastoma patients. ONC201 achieved…

Isabel Arrillaga-Romany, MD, PhD of @MGHNeuroOnc @Oncoceutics discusses the clinical efficacy of weekly ONC201 in adult recurrent glioblastoma. ________ Oncoceutics, Inc. announced that results from the second and third cohort of the Phase II trial for patients with recurrent glioblastoma treated with the company’s lead imipridone, ONC201, were recently published in the journal Neuro-Oncology. This manuscript represents the third publication among a series of reports demonstrating durable radiographic regressions with ONC201 in patients with H3 K27M-mutant glioma. The study (NCT02525692) also demonstrated that weekly oral administration of ONC201 given as a single agent was well-tolerated, achieved therapeutic intratumoral concentrations, and intratumoral pharmacodynamic activity in adult recurrent glioblastoma…

Data to include early analyses of Stivarga® (regorafenib) across HCC, CRC and GI cancers, including Phase 1b data in combination with immuno-oncology therapies New analysis of efficacy and safety from the NAVIGATE trial for Vitrakvi® (larotrectinib) in gastrointestinal tumors will be presented Abstracts: 564, 542, 135, 158, 824 Bayer will present new research from the Company’s oncology portfolio, including Stivarga® (regorafenib) and Vitrakvi® (larotrectinib), at the 2020 American Society of Clinical Oncology Gastrointestinal (ASCO GI) Cancers Symposium, taking place January 23-25 in San Francisco, California. The presentations will feature data on Stivarga in hepatocellular carcinoma (HCC) and gastric and colorectal cancers, as…

In Roswell Park study, 42% of patients who received gabapentin for pain managementrequired no narcotics Most patients treated for head and neck cancer experience painful mouth sores Team tested how well gabapentin controlled pain, at both low and high doses Both gabapentin and methadone can be more effective than standard approaches With nearly all patients who undergo treatment for cancers of the head and neck experiencing oral mucositis, or painful mouth sores, effective pain control is one of the main goals of physicians and care teams. Looking to provide more effective relief for patients while also reducing the need for…

Thomas Powles, MD, MBBS @tompowles1 of @QMBCI discusses how the JAVELIN study affects clinicians and treatment today.

Thomas Powles, MD, MBBS @tompowles1 of @QMBCI answers common questions regarding the JAVELIN study including what happens to patients with progression of disease?

Thomas Powles, MD, MBBS @tompowles1 of @QMBCI explains the phase III JAVELIN study in urothelial cancer.

Soumyajit Roy, MBBS @SouMyajiT_RO of University of Ottawa Division of Radiation Oncology, Department of Radiology discusses the impact of therapy with external-beam radiotherapy in localized prostate cancer: what is next for treatment?

Soumyajit Roy, MBBS @SouMyajiT_RO of University of Ottawa Division of Radiation Oncology, Department of Radiology discusses the impact of therapy with external-beam radiotherapy in localized prostate cancer: a phase III randomized controlled trial.

Soumyajit Roy, MBBS @SouMyajiT_RO of University of Ottawa Division of Radiation Oncology, Department of Radiology discusses androgen-deprivation therapy with external-beam radiotherapy in localized prostate cancer: is there a correlation between the target volume of radiation?

World’s first combination of tumor-targeted, off-the-shelf PD-L1-targeted Natural Killer cells with IL-15 fusion protein (N-803) to induce immune system activation of both the NK and T-cells demonstrated complete response in second-line metastatic pancreatic cancer, confirmed by PET/CT scan. ·       Results consistent with durable complete responses recently reported in Triple Negative Breast Cancer (TNBC) when off-the-shelf CD-16 NK therapy was combined with ImmunityBio’s N-803. ·       Over 130 doses of PD-t-haNK cells safely administered in Phase 1 trial with no severe treatment-related adverse side effects. ·       NantKwest plans to initiate registration trials in recurrent metastatic TNBC and pancreatic cancer patients that failed standard of care. ·       N-803…

Soumyajit Roy, MBBS @SouMyajiT_RO of University of Ottawa Division of Radiation Oncology, Department of Radiology discusses androgen-deprivation therapy with external-beam radiotherapy in localized prostate cancer: a phase III randomized controlled trial.

Patrick Therasse, MD of Servier Group discusses Servier’s R&D efforts in oncology.

First Surveillance Tests Designed to Enable Community Hospitals and Labs to Deliver Rapid, Accurate and Actionable Genomic Information to Oncology Physicians and Patients Across Care Settings BOULDER, Colo., Jan. 14, 2020 /PRNewswire/ — ArcherDX, Inc., today announced it has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for its Personalized Cancer Monitoring (PCM) technology, a bespoke, minimally-invasive and highly-sensitive product intended for early-stage cancer treatment monitoring and recurrence surveillance. ArcherDX’s technology enables healthcare providers across community and academic care settings access to genomic information in their laboratory, saving critical time and allowing world-class, cost-effective care locally.…

Brain Tumor Center affiliated with Providence Saint John’s Health Center The approved lung cancer drug pemetrexed is at the center of a new clinical trial at Providence Saint John’s Health Center’s Pacific Brain Tumor Center for patients diagnosed with chordoma, a rare, slow-growing cancer found in the bones at the base of the skull and the spine that is difficult to treat. Two chordoma patients who received the drug – approved by the FDA for lung cancer only – showed promising results with reductions in the sizes of their tumors. Drs. Santosh Kesari and Tiffany Juarez   Chordoma is an extremely rare cancer, diagnosed…

Caris Life Sciences®, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, today announced the launch of the newest addition to its comprehensive genomic profiling offerings, MI GPSâ„¢ (Genomic Profiling Similarity) Score. MI GPS Score is an AI driven tumor type biology similarity score that uses more than 6500 mathematical models in the machine learning algorithm to compare molecular characteristics of a patient’s tumor against Caris’ extensive database to provide new insights into the molecular subtype of cancer of unknown primary (CUP) cases, atypical clinical presentation cases, and other difficult to treat cancer cases, to…

Caris Life Sciences®, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, today announced the launch of the newest addition to its comprehensive genomic profiling offerings, MI GPSâ„¢ (Genomic Profiling Similarity) Score. MI GPS Score is an AI driven tumor type biology similarity score that uses more than 6500 mathematical models in the machine learning algorithm to compare molecular characteristics of a patient’s tumor against Caris’ extensive database to provide new insights into the molecular subtype of cancer of unknown primary (CUP) cases, atypical clinical presentation cases, and other difficult to treat cancer cases, to…

Caris Life Sciences®, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, today announced the launch of the newest addition to its comprehensive genomic profiling offerings, MI GPSâ„¢ (Genomic Profiling Similarity) Score. MI GPS Score is an AI driven tumor type biology similarity score that uses more than 6500 mathematical models in the machine learning algorithm to compare molecular characteristics of a patient’s tumor against Caris’ extensive database to provide new insights into the molecular subtype of cancer of unknown primary (CUP) cases, atypical clinical presentation cases, and other difficult to treat cancer cases, to…

ACE1702 is a potential off-the-shelf cell therapy developed using Acepodia’s Antibody-Cell Conjugation technology Acepodia, a biotechnology company developing cancer immunotherapy based on its novel ACCâ„¢ (Antibody Cell-Conjugation) technology platform, today announced it has received clearance of its Investigational New Drug (IND) application from the US Food and Drug Administration (FDA) to initiate a Phase 1 clinical study of its natural killer (NK) cell therapy and lead drug candidate ACE1702 in patients with HER2-expressing solid tumors. “The FDA’s clearance of our IND for ACE1702 is a major milestone for Acepodia that represents an important initial validation of our ACCâ„¢ platform, which…

Caris Life Sciences®, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, today announced the launch of the newest addition to its comprehensive genomic profiling offerings, MI GPSâ„¢ (Genomic Profiling Similarity) Score. MI GPS Score is an AI driven tumor type biology similarity score that uses more than 6500 mathematical models in the machine learning algorithm to compare molecular characteristics of a patient’s tumor against Caris’ extensive database to provide new insights into the molecular subtype of cancer of unknown primary (CUP) cases, atypical clinical presentation cases, and other difficult to treat cancer cases, to…

Combination of Defactinib and CH5126766 Shows Promise in Treating KRAS Mutant Solid Tumors in Clinical Trial Clinical Data Presentation and Regulatory Discussions Planned for 1H 2020 Verastem, Inc. (Nasdaq:VSTM) (Verastem Oncology or the Company), a biopharmaceutical company focused on developing and commercializing medicines seeking to improve the survival and quality of life of cancer patients, today announced a global licensing agreement with Chugai Pharmaceutical Co., Ltd., (Chugai) whereby Verastem Oncology is obtaining worldwide development and commercialization rights to the RAF/MEK inhibitor CH5126766 (CKI27) from Chugai currently under development for the treatment of KRAS mutant solid tumors. The Company will host an investor…

More central line-associated blood infections and catheter malfunctions seen with PICCs A new study provides convincing evidence that the use of peripherally inserted central catheters (PICCs) to administer medicine and draw blood in children is associated with a significantly increased risk of blood clots (known as venous thromboembolism or VTE) compared with central venous catheters (CVCs) placed directly into the neck or chest. The study results, published today in Blood, also reveal a significantly higher rate of CVC-related bloodstream infections and catheter malfunctions among pediatric patients receiving PICCs. Based on the findings, researchers are voicing concerns about the growing use of PICCs –…

Hans Hammers, MD of UT Southwestern Medical Center discusses the role of radiation in kidney cancer at the KCA 2019.

Source: https://www.spreaker.com/user/cancergrace/narjust-duma-md-introduces-cancer-myths- GRACE is excited to bring to you a new series on Cancer Myths in the Latin Community. Our friend and partner, Narjust (N.J.) Duma, MD is a Chief Hematology/Medical Oncology Fellow at Mayo Clinic in Rochester, MN. Dr. Duma is committed to her research and advocacy in diversity and inclusion. She was recognized as the 2018 resident of the year by the National Hispanic Medical Association. N.J. speaks to cancer myths in the Latino community, and in this video N.J. introduces herself and the following series. See more at cancerGRACE.org.

GRACE is very excited to bring you more of our program on supportive care in cancer treatment.Arjun Gupta, MD, one of the GRACE Fellows Ambassador Program Winners for 2019 is the host of this video series, Supportive Care in Cancer Treatment. In this video, Dr. Gupta’s guest is Dr. Dawn Hershman, with Columbia University in New York. Their topic of discussion is Aromatase Inhibitor Induced Arthralgia (AI Induced Arthralgia).For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

Thank you all for joining us for our live stream today! If you have questions please feel free to email us at info@cancerGRACE.org, or go to our community forum at https://cancergrace.org/forum.

GRACE is excited to bring you new information in our Bladder Cancer Program. For this first video of 2019, Dr. Ramy Sedhom introduces us to Dr. Elizabeth Plimack with Fox Chase Cancer Center. Dr. Plimack offers information on the role of immunotherapy in bladder cancer. For more, please visit http://cancerGRACE.org/. For questions or to join the conversation, visit https://cancergrace.org/forum.

GRACE is excited to bring to our Spanish speaking community information on Cancer Basics.Our friend and partner, Narjust (N.J.) Duma, MD is a Chief Hematology/Medical Oncology Fellow at Mayo Clinic in Rochester, MN. Dr. Duma is committed to her research and advocacy in diversity and inclusion. She was recognized as the 2018 resident of the year by the National Hispanic Medical Association.Dr. Duma discusses cancer basics for the Latino community, and in this video N.J. discusses the basics of immunotherapy.Stay tuned for more great videos!If you want to join the conversation, please visit our forums! For more, please visit http://cancerGRACE.org/.…

Androgen Deprivation Therapy (ADT) for Men with Prostate Cancer GRACE is very excited to bring to more info from our new program, Supportive Care in Cancer Treatment. Ramy Sedhom, MD, with Johns Hopkins in Baltimore, Maryland, hosts this episode of Supportive Care in Cancer Treatment. In this video Dr. Sedhom and his guest, Dr. Tyler Stewart with the Moores Cancer Center, UC San Diego, discuss Androgen Deprivation Therapy or ADT for men with prostate cancer. To join the conversation, visit https://cancergrace.org/forum. To find additional CancerGRACE resources, visit https://cancergrace.org. To donate to CancerGRACE, visit https://cancergrace.org/donate.

GRACE is excited to bring you new information in our Bladder Cancer Program. For this video, Dr. Ramy Sedhom introduces us to Dr. Matthew Galsky with the Tisch Cancer Institute and Icahn School of Medicine at Mt. Sinai in New York. Dr. Galsky discusses information on the role of immunotherapy in metastatic bladder cancer.For more, please visit http://cancerGRACE.org/. For questions or to join the conversation, visit https://cancergrace.org/forum.

Dr. Duma is an Assistant Professor and Thoracic Oncologist at @UWcarbone, University of Wisconsin Carbone Cancer Center, and Former Chief Fellow @MayoClinic in Rochester, Minnesota. We are pleased to present more information for the Latino community on cancer basics. In this video Dr. Duma speaks with Dr. Maria Daniela Martin, and discusses the basics of immunotherapy. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

Ramon Parsons, MD, PhD @Ramon_Parsons of @IcahnMountSinai discusses a novel agent that degrades a protein called EZH2 that drives the growth of triple negative breast cancer in cancer cell lines and live models. This research also showed that the agents which inhibit the enzymatic activity of EZH2 but do not degrade EZH2 did not work in triple negative breast cancer.

·         At the planned interim analysis, Phase III JAVELIN Bladder 100 study met the primary endpoint of prolonging overall survival (OS) as a first-line maintenance treatment versus standard of care ·         BAVENCIO is the first immunotherapy to significantly prolong OS in locally advanced or metastatic urothelial carcinoma (UC) in the first-line setting in a Phase III trial   EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the US and Canada, and Pfizer Inc. (NYSE: PFE) today announced the Phase III JAVELIN Bladder 100 study met its primary endpoint of overall survival (OS) at the planned interim analysis. In this…

Ramon Parsons, MD, PhD @Ramon_Parsons of @IcahnMountSinai discusses a novel agent that degrades a protein called EZH2 that drives the growth of triple negative breast cancer in cancer cell lines and live models. This research also showed that the agents which inhibit the enzymatic activity of EZH2 but do not degrade EZH2 did not work in triple negative breast cancer.

The Department of Neurosurgery at the Icahn School of Medicine at Mount Sinai has received more than $10 million in federal funding for several projects focusing on brain tumor research. The newest grant focuses on the use of magnetic hyperthermia therapy (MHT), a powerful nanotechnology-based treatment that may enhance the effects of radiation therapy and chemotherapy on glioblastoma tumors. The lead investigator is Constantinos Hadjipanayis, MD, PhD, Director of Neurosurgical Oncology at the Mount Sinai Health System and Chair of Neurosurgery at Mount Sinai-Union Square. “Our neurosurgeons are at the forefront of clinical care and scientific research with the goal…

– Data from pivotal study demonstrate safety and efficacy regardless of prior gastrectomy in previously treated patients with metastatic gastric cancer (mGC) and gastroesophageal junction (GEJ) adenocarcinoma   PRINCETON, N.J., October 14, 2019 – Taiho Oncology, Inc. announced today that detailed results from the analysis of patients with prior gastrectomy enrolled in the Phase 3 TAS-102 Gastric Study (TAGS) evaluating LONSURF® (trifluridine and tipiracil) in adult patients with metastatic gastric or gastroesophageal junction adenocarcinoma previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropriate, HER2/neu-targeted therapy, were published in the…

Betty Hamilton, MD of @ClevelandClinic discusses the post-transplant work statue of young adult survivors of allogeneic hematopoietic cell transplant.

Abby Statler, MD of @ClevelandClinic answers if racial disparities in AML are associated with organ dysfunction.

Ajay K. Nooka, MD of @WinshipAtEmory discusses multiple myeloma disparities.

Robert Kreitman, MD of National Cancer Institute discusses Lumoxiti® phase III trial in patients with relapsed or refractory hairy cell leukemia.

Allison M. Winter, MD of @ClevelandClinic discusses comparative outcomes of relapsed follicular lymphoma patients treated with novel agents.

Hope Rugo, MD of @UCSFMedicine discusses the SOPHIA Study. _____________ MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today presented updated results from the Phase 3 SOPHIA study comparing margetuximab plus chemotherapy versus trastuzumab plus chemotherapy in patients with HER2-positive metastatic breast cancer who have previously been treated with anti-HER2-targeted therapies. Margetuximab is an investigational, immune-enhancing monoclonal antibody derived from the Company’s proprietary Fc-engineering technology platform. The data were presented today during an oral session at the San Antonio Breast Cancer Symposium (SABCS) by Dr. Hope Rugo, M.D.,…

MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today presented updated results from the Phase 3 SOPHIA study comparing margetuximab plus chemotherapy versus trastuzumab plus chemotherapy in patients with HER2-positive metastatic breast cancer who have previously been treated with anti-HER2-targeted therapies. Margetuximab is an investigational, immune-enhancing monoclonal antibody derived from the Company’s proprietary Fc-engineering technology platform. The data were presented today during an oral session at the San Antonio Breast Cancer Symposium (SABCS) by Dr. Hope Rugo, M.D., Director, Breast Oncology and Clinical Trials Education, University of California San…

Luca Malorni, MD of Prato Hospital discusses a marker in operable breast cancer at SABCS 19. __________ The study is a retrospective analysis on serum samples from a randomized clinical trial comprising 644 women with operable breast cancer (premenopausal with stage II-IIIB HR+ breast cancer). Serum samples were collected pre-operatively on the day of surgery. After five years, patients with low pre-operative DiviTum values (the lowest quartile, <25 percent) showed a disease-free survival rate of 81 percent versus 58 percent in the group with the highest DiviTum values (>75 percent). “We are thrilled to see these new, interesting results. It…

Luca Malorni, MD of Prato Hospital discusses a marker in operable breast cancer at SABCS 19. __________ The study is a retrospective analysis on serum samples from a randomized clinical trial comprising 644 women with operable breast cancer (premenopausal with stage II-IIIB HR+ breast cancer). Serum samples were collected pre-operatively on the day of surgery. After five years, patients with low pre-operative DiviTum values (the lowest quartile, <25 percent) showed a disease-free survival rate of 81 percent versus 58 percent in the group with the highest DiviTum values (>75 percent). “We are thrilled to see these new, interesting results. It…

Jennifer Crozier, MD of @BaptistHealthSA discusses the FLEX real world data in early stage breast cancer.

William Audeh, MD of @Agendia discusses new data presented at SABCS demonstrating how genomic profiling benefits early stage breast cancer.

Jay Andersen, MD of Compass Oncology discusses the phase 3 KEYNOTE-522 trial was investigating KEYTRUDA (pembrolizumab), Merck’s anti-PD-1 immunotherapy, in combination with chemotherapy that was designed for patients with TNBC.         pembrolizumab, keytruda, phase 3, keynote-522 trial, merck’s anti-pd-1 immunotherapy, immunotherapy, patients with tnbc, tnbc

Rafella Colombatti of University of Padova discusses the European perspective on sickle cell research.

Andrew Campbell, MD of Children’s National Hospital discusses the CASiRE study.

Peter Voorhees, MD of @LevineCancer discusses the depth of response to dara, lenalidomide, bortezomib, and dexamethasone (RVd) improves over time in patients with transplant-eligible newly diagnosed multiple myeloma: GRIFFIN study update.

Timothy Illidge, MD, PhD of @OfficialUoM provides analysis of brentuximab vedotin plus CHP (A+CHP) in the frontline treatment of patients with CD30+ peripheral T-Cell lymphomas (ECHELON-2).

Tanya Siddiqi, MD of @cityofhope discusses the updated results from transcend CLL 004, a Phase 1/2 study including patients with high-risk disease treated with ibrutinib.

Chadi Nabhan, MD MBA of Aptitude Health discusses potential of biosimilars in treatment of blood cancer.

– Jazz to pay an upfront payment of $200 million to PharmaMar – Opportunity for Jazz to expand its oncology portfolio with lurbinectedin, a late stage asset in relapsed small cell lung cancer (SCLC) – PharmaMar is also eligible to receive up to $800 million in potential milestone payments in addition to royalties on net sales – Lurbinectedin New Drug Application (NDA) submitted to FDA in December 2019 with the potential to launch in 2020 Collaboration emphasizes Jazz and PharmaMar’s commitments to providing differentiated medicines to patients in areas of high unmet need PharmaMar (MSE:PHM) and Jazz Pharmaceuticals plc (Nasdaq:JAZZ) today announced that PharmaMar…

Shyamala Navada, MD of @MountSinaiNYC discusses the phase II study of oral rigosertib combined with azacitidine as first line therapy in patients with HR-MDS.

Jeff Sharman, MD of @TheUSONetwork discusses the phase III ELEVATE TN trial. _______ Read here: https://www.oncologytube.com/video/calquence-significantly-prolonged-the-time-patients-lived-without-disease-progression-or-death-in-previously-untreated-chronic-lymphocytic-leukemia?channelName=Cancer-News

Full results from Phase III ELEVATE TN trial showed 93% of patients on CALQUENCE combined with obinutuzumab vs. 47% of patients on chlorambucil plus obinutuzumab remained free of disease progression or death at 24 months Trial also showed 87% of patients on CALQUENCE alone remained free of disease progression or death at 24 months AstraZeneca today presented results from the interim analysis of the Phase III ELEVATE TN trial, showing that CALQUENCE® (acalabrutinib) combined with obinutuzumab or as monotherapy significantly improved progression-free survival (PFS) compared to chlorambucil plus obinutuzumab, a standard chemo-immunotherapy treatment, in patients with previously untreated chronic lymphocytic leukemia…

Saro Armenian, DO of @cityofhope discusses the long term morbidity by survivors of AML treated with blood or marrow transplantation.

Professor Simon Rule of Plymouth University Medical School discusses long term outcomes with ibrutinib versus the prior regimen.

Roman Hajek, MD of University of Ostrava discusses MM patients remaining under represented in clinical trials based on standard laboratory parameters.

Robert Rifkin, MD of @TheUSONetwork discusses the Lyra study.

Aziz Nazha, MD of @CleClinicMD discusses a personalized prediction model to risk stratify patients with AML.

Mohamed Zaki, MD of @abbvie discusses the phase 3 MURANO trial. ________ Read here: https://www.oncologytube.com/video/new-long-term-data-continues-to-demonstrate-progression-free-survival-and-overall-survival-benefits-with-venclexta-venclyxto-venetoclax-combination-in-patients-with-relapsed-refractory-ch-1

Four-year updated analysis from the MURANO trial showed an 81% reduction in the risk of disease progression or death in patients treated with VENCLEXTA®/VENCLYXTO® (venetoclax) plus rituximab (VenR) and higher rates of minimal residual disease (MRD)-negativity compared to bendamustine plus rituximab (BR)[1] – The risk of death was decreased by 59% in the 130 patients who completed VenR, versus BR, despite 79% of patients in the BR arm who went on to receive a novel targeted treatment. Median overall survival (OS) was not reached for either treatment group[1] – Sixty-eight percent of the 130 patients who completed the treatment course…

Michael Wang, MD @michaelwangmd of @MDAndersonNews discusses KTE-X19, an anti-CD19 chimeric antigen receptor (CAR) T cell therapy, in patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL): results of the phase 2 ZUMA-2 study.

Jesus Berdeja, MD @BerdejaJesus of Sarah Cannon Center for Blood Cancers discusses the phase 1 clinical study of bb21217.

Jan G. J. van de Winkel, Ph.D of @Genmab announces data to be presented at ASH 2019 including data from ongoing phase I DuoBody®-CD3xCD20 (GEN3013) trial.

Jan Hillson, MD of @AlpineImmuneSci disucsses ALPN-101.

Steven Horwitz, MD of @sloan_kettering discusses the phase 2 PRIMO study. _______ Verastem, Inc. (Nasdaq:VSTM) (Verastem Oncology or the Company), a biopharmaceutical company focused on developing and commercializing medicines seeking to improve the survival and quality of life of cancer patients, today announced the presentation of key abstracts highlighting COPIKTRA® (duvelisib) data at the American Society of Hematology 2019 Annual Meeting taking place December 7-10, 2019, in Orlando.   “Given the aggressive nature of peripheral T-cell lymphoma (PTCL) and the lack of effective therapeutic options for these patients, we are pleased to present data from the dose optimization phase of our…

Duvelisib Achieves Overall Response Rate of 62% in Patients with Relapsed or Refractory PTCL with Manageable Safety Profile in Initial Phase of PRIMO Trial   Data Presented Supports Potential of Duvelisib Across Indications, Lines of Therapy and in Combination   Verastem, Inc. (Nasdaq:VSTM) (Verastem Oncology or the Company), a biopharmaceutical company focused on developing and commercializing medicines seeking to improve the survival and quality of life of cancer patients, today announced the presentation of key abstracts highlighting COPIKTRA® (duvelisib) data at the American Society of Hematology 2019 Annual Meeting taking place December 7-10, 2019, in Orlando.   “Given the aggressive nature…

Aaron Gerds, MD of @CleClinicMD discusses the phase 2 study of luspatercept in patients with myelofibrosis-associated anemia

Aaron Gerds, MD of @CleClinicMD discusses the phase 2 study of luspatercept in patients with myelofibrosis-associated anemia

Fredrik Schjesvold, MD of Oslo University College addresses how this affects clinicians and what is next for research.

Fredrik Schjesvold, MD of Oslo University College disucsses the ICARIA-MM study.

Eric Fedyk, PhD of @TakedaPharma discusses the binding of CD38 therapeutics to red blood cells and platelets subverts depletion of target cells.

Eunice Wang, MD of @RoswellPark discusses cladribine, cytarabine, granulocyte colony stimulating factor ± mitoxantrone (CLAG ± M) is highly effective therapy for secondary and relapsed/refractory AML.

Shouryadeep Srivastava, MBBS, PhD of @TakedaOncology discusses CML patients prescribed ponatinib vs bosutinib: what is next for research?

Shouryadeep Srivastava, MBBS, PhD of @TakedaOncology discusses CML patients prescribed ponatinib vs bosutinib.

Dawn Marie Stull, PharmD of @TakedaOncology discusses closing the efficacy and effectiveness gap: outcomes in relapsed/refractory multiple myeloma (RRMM) patients (Pts) treated with ixazomib-lenalidomide-dexamethasone (IRd) in routine clinical practice remain comparable to the outcomes reported in the phase 3 tourmaline-MM1 study.

Dawn Marie Stull, PharmD of @TakedaOncology discusses closing the efficacy and effectiveness gap: outcomes in relapsed/refractory multiple myeloma (RRMM) patients (Pts) treated with ixazomib-lenalidomide-dexamethasone (IRd) in routine clinical practice remain comparable to the outcomes reported in the phase 3 tourmaline-MM1 study.

David Gilham, MD of Celyad discusses a human NKG2D receptor-based CAR-T cell that potentially targets 80% of all cancers.

Christopher Yasenchak, MD of @TheUSONetwork discusses the phase 2 study of frontline brentuximab vedotin plus nivolumab.

Brian Hill, MD of Cleveland Clinic @ClevelandClinic discusses KTE-X19

Baiyan Wang, MD of Hospital of Xi’an Jiaotong University discusses the LEGEND-2 data.

Nizar Bahlis, MD of University of Calgary discusses patients with newly diagnosed multiple myeloma (MM) ineligible for transplant: updated analysis of MAIA.

Alexey Danilov, MD of @OHSUNews discusses pharmacologic inhibition of SUMO-activating enzyme (SAE) with TAK-981 augments interferon signaling and regulates t cell differentiation.

– TAILORx Study Featured in William L. McGuire Memorial Lecture Award at 2019 San Antonio Breast Cancer Symposium® – New Publication of Long-term Data from Real-world Clinical Practice Confirms Conclusions of TAILORx   Exact Sciences Corp. (NASDAQ: EXAS) today announced new outcomes data from two large population-based studies1,2 presented at the 2019 San Antonio Breast Cancer Symposium (SABCS®). The real-world evidence suggests that use of the Oncotype DX Breast Recurrence Score® test in clinical practice is consistent with previous clinical validation studies including TAILORx, the largest ever breast cancer treatment trial. This landmark study was featured in the William L. McGuire Memorial Lecture Award, which recognized Joseph A.…

Jarrod Dalton, MD and David Zidar, MD of @CleClinicMD discuss lymphopenia associated with death due to heart disease, cancer and respiratory infections, including influenza and pneumonia. ___________ A new collaborative study led by Cleveland Clinic and University Hospitals has found that commonly used clinical indicators of immune status and inflammation can predict mortality in the general population. Published in JAMA Network Open, the study showed that lymphopenia (a condition characterized by low levels of a specific type of white blood cell, called lymphocytes) is associated with death due to heart disease, cancer and respiratory infections, including influenza and pneumonia. This relationship…

Agne Paner, MD of @RushMedical discusses updated data from the phase 2 HORIZON study. __________ Oncopeptides AB (Nasdaq Stockholm: ONCO) will today present follow-up data from the pivotal Phase 2 HORIZON (OP-106) study at the ASH Annual Meeting 2019. Melflufen showed an overall response rate (ORR) of 29% and clinical benefit rate (CBR) of 37% in patients with late-stage relapsed/refractory multiple myeloma (RRMM). The safety profile remained consistent with prior reports from the HORIZON study. These data reinforce Oncopeptides’ view that melflufen can play a role in the treatment of patients with RRMM and the Company plans to submit a New Drug Application (NDA)…

Jarrod Dalton, MD and David Zidar, MD of @CleClinicMD discuss lymphopenia associated with death due to heart disease, cancer and respiratory infections, including influenza and pneumonia. ____________ A new collaborative study led by Cleveland Clinic and University Hospitals has found that commonly used clinical indicators of immune status and inflammation can predict mortality in the general population. Published in JAMA Network Open, the study showed that lymphopenia (a condition characterized by low levels of a specific type of white blood cell, called lymphocytes) is associated with death due to heart disease, cancer and respiratory infections, including influenza and pneumonia. This relationship…

Jennifer Crombie, MD of @DanaFarber discusses a phase I study of duvelisib and venetoclax in patients with relapsed or refractory CLL / SLL.

John Mascarenhas, MD of @MountSinaiNYC discusses MANIFEST, a phase 2 study of CPI-0610, a bromodomain and extraterminal domain inhibitor (BETi)

Nikhil Munshi of @DanaFarber discusses the phase I study evaluating interleukin-15 (IL-15) receptor agonist, NKTR-255 in MM and NHL.

Nektar Therapeutics (NASDAQ: NKTR) today announced three presentations at the 61st American Society of Hematology (ASH)   Annual Meeting & Exposition for its IL-15 agonist and investigational candidate, NKTR-255. Data were presented from a number of preclinical studies conducted in collaboration with researchers from the Dana Farber Cancer Institute and the Fred Hutchinson Cancer Research Center. NKTR-255 is an interleukin-15 (IL-15) receptor agonist, which is currently being evaluated in a Phase 1 clinical study in patients with multiple myeloma (MM) and non-Hodgkin’s lymphoma (NHL). NKTR-255 is designed to work by selectively targeting the IL-15 pathway to expand both natural killer…

Loui Madakamutil, PhD of Nektar Therapeutics discusses new preclinical Ddta for its IL-15 agonist, NKTR-255 at ASH 2019. ___________ Read here: https://www.oncologytube.com/video/nektar-therapeutics-announces-presentation-of-new-preclinical-data-for-its-il-15-agonist-nktr-255-at-the-american-society-of-hematology-ash-2019-annual-meeting

MONALEESA-3 paper published today in The New England Journal of Medicine shows statistically significant overall survival results for Kisqali plus fulvestrant, reducing the risk of death by almost 30%   Overall survival benefit for Kisqali plus fulvestrant was consistent regardless of line of therapy or response to prior endocrine treatment   Kisqali is the only CDK4/6 inhibitor to demonstrate consistently superior overall survival in two Phase III trials, proven with multiple combination partners and in two distinct patient populations   — MONALEESA-3 data published today in The New England Journal of Medicine (NEJM) shows Kisqali® (ribociclib) plus fulvestrant demonstrated a statistically significant improvement in overall…

John Seymour, PhD of @PeterMacCC discusses year analysis of murano study confirms sustained benefit of time-limited venetoclax-rituximab (VenR) in relapsed refractory (R/R) chronic lymphocytic leukemia (CLL).

Alexander Cohen, MBBS of Guys’ and St. Thomas’ NHS Foundation Trust answers the common questions asked about the safety and effectiveness of apixaban, LMWH, and warfarin among venous thromboembolism patients with active cancer.

Alexander Cohen, MBBS of Guys’ and St. Thomas’ NHS Foundation Trust discusses the safety and effectiveness of apixaban, LMWH, and Warfarin among venous thromboembolism patients with active cancer.

Thanos Zomas, MD of @TakedaOncology on brentuximab vedotin with chemotherapy for stage 3/4 classical hodgkin lymphoma (cHL): what’s next in research and exciting news at ASH 2019

Thanos Zomas, MD of @TakedaOncology discusses brentuximab vedotin with chemotherapy for stage 3/4 classical hodgkin lymphoma (cHL): 4-year update of the echelon-1 study.

Ifeyinwa (Ify) Osunkwo, MD of @LevineCancer explains the SWAY study on sickle cell disease.

Ifeyinwa (Ify) Osunkwo, MD of @LevineCancer discusses the unmet needs in sickle cell research.

Ifeyinwa (Ify) Osunkwo, MD of @LevineCancer discusses the unmet needs in sickle cell research.

Con Tam, MD of @PeterMacCC discusses the phase 2 CAPTIVATE clinical trial in CLL.: how this will affect clinicians and treatment.

Con Tam, MD of @PeterMacCC discusses the phase 2 CAPTIVATE clinical trial in CLL.

Rajat Bannerji, MD of @RutgersCancer provides an update on Phase I REGN1979.         ash 2019, rutgers cancer, regn1979, phase I, phase I regn1979, update

Dennis Cooper, MD of @RutgersCancer provides detail on his upcoming presentation at ASH about clinical data on REGN5458

Zsuzsanna Devecseri, MD of @SanofiGenzyme @sanofi discusses the pivotal Phase 3 ICARIA-MM trial of isatuximab, an investigational anti-CD38 monoclonal antibody, in relapsed/refractory multiple myeloma (RRMM) presented at the ASH.

Deepu Madduri, MD @DMadduri of @MountSinaiNYC @IcahnMountSinai discusses the CARTITUDE-1: a phase 1b/2 study of JNJ-4528, a CAR-T cell therapy directed against b-cell maturation antigen (BCMA), in patients with relapsed and/or refractory multiple myeloma (R/R MM). Patients with multiple myeloma who had received a median of five prior therapies, and for whom standard-of-care treatments were no longer working, had a high response rate when treated with the investigational CAR T-cell therapy JNJ-4528, which targets BCMA, an antigen a protein commonly found on the surface of multiple myeloma cancer cells. Researchers said that JNJ-4528 is a novel CAR T-cell therapy featuring…

Deepu Madduri, MD @DMadduri of @MountSinaiNYC @IcahnMountSinai discusses the CARTITUDE-1: a phase 1b/2 study of JNJ-4528, a CAR-T cell therapy directed against b-cell maturation antigen (BCMA), in patients with relapsed and/or refractory multiple myeloma (R/R MM). Patients with multiple myeloma who had received a median of five prior therapies, and for whom standard-of-care treatments were no longer working, had a high response rate when treated with the investigational CAR T-cell therapy JNJ-4528, which targets BCMA, an antigen a protein commonly found on the surface of multiple myeloma cancer cells. Researchers said that JNJ-4528 is a novel CAR T-cell therapy featuring…

Mark Sellmyer, MD, PhD @sellmyerlab of @PennMedicine explains how CAR-T cell imaging markers will affect treatment and clinicians. ___________ Read here: https://www.eurekalert.org/pub_releases/2019-11/uops-tmc110519.php

Mark Sellmyer, Md, PhD @sellmyerlab of @PennMedicine answers how sensitive is this technology? ___________ Read here: https://www.eurekalert.org/pub_releases/2019-11/uops-tmc110519.php

Mark Sellmyer, MD, PhD sellmyerlab of @PennMedicine discusses to monitor cancer therapy, researchers tag CAR-T cells with imaging markers. ___________ Read here: https://www.eurekalert.org/pub_releases/2019-11/uops-tmc110519.php

Dr. Susan Branford

Dr. Jorge Cortez

American doctor and cancer research scientist, Dr. William G. Kaelin, Jr. (Harvard University and Dana Farber Cancer Institute), along with 2 colleagues, Sir Peter Ratcliffe (University of Oxford, United Kingdom) and Dr. Gregg Semenza (Johns Hopkins University) have been selected as the 2019 Nobel Prize in Medicine recipients for their discoveries of how cells sense and adapt to oxygen availability. This work has been completed through the understanding of the von Hippel-Lindau (VHL) gene and is enabling better understanding of abnormal cell or cancer growth. “The work of these three men, and particularly Dr. Kaelin, who has focused on the…

Dr. Ekaterina Chelsheva

Responses observed at all dose levels in Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL), including patients with BTK Resistance, BTK Intolerance, and BCL2 Resistance Eli Lilly and Company (NYSE: LLY) today announced interim clinical data from the LOXO-305 global Phase 1/2 BRUIN dose escalation trial. LOXO-305 is an investigational, highly selective, non-covalent Bruton’s tyrosine kinase (BTK) inhibitor. These data were presented today at the 2019 American Society of Hematology (ASH) Annual Meeting in Orlando (abstract 501). At all doses studied, LOXO-305 delivered objective responses in patients who had received diverse prior therapies and had exhibited varied molecular mechanisms…

Dr. Carla Bouqimpani

Final analysis expands on efficacy results from pivotal Phase III trial of Lumoxiti in hairy cell leukemia; durable, complete responses maintained in long-term follow-up data   Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) shared new, long-term data from the pivotal Phase III trial of Lumoxiti (moxetumomab pasudotox-tdfk) today at the 61st American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando, USA, which expands on the efficacy results and affirms the manageable safety profile of the medicine.    The final analysis showed that 36 percent (29/80) of the relapsed or refractory hairy cell leukemia patients achieved…

– Four-year updated analysis from the MURANO trial showed an 81% reduction in the risk of disease progression or death in patients treated with VENCLEXTA®/VENCLYXTO® (venetoclax) plus rituximab (VenR) and higher rates of minimal residual disease (MRD)-negativity compared to bendamustine plus rituximab (BR)[1] – The risk of death was decreased by 59% in the 130 patients who completed VenR, versus BR, despite 79% of patients in the BR arm who went on to receive a novel targeted treatment. Median overall survival (OS) was not reached for either treatment group[1] – Sixty-eight percent of the 130 patients who completed the treatment…

NDA Submission for Accelerated Approval of Tazemetostat for Patients with Relapsed or Refractory Follicular Lymphoma on Track for December 2019 Epizyme, Inc. (Nasdaq: EPZM), a late-stage biopharmaceutical company developing novel epigenetic therapies, today reported positive, mature data at the 2019 American Society of Hematology (ASH) Annual Meeting from its ongoing Phase 2 trial of tazemetostat, an oral EZH2 inhibitor, as a monotherapy for patients with follicular lymphoma (FL), both with or without EZH2 activating mutations, who have received at least two prior lines of systemic therapy. The data show that treatment with tazemetostat demonstrated meaningful clinical activity as assessed by…

Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today announced that new results from its MGTA-145 stem cell mobilization program were presented at the 61st Annual Meeting of the American Society of Hematology (ASH). These results, which were presented by John DiPersio, M.D., Ph.D., Professor of Medicine and Chief of the Oncology Division, Washington University School of Medicine, St. Louis, Missouri, showed that MGTA-145 in combination with plerixafor met all the endpoints in the study, and safely mobilized a large number of high-quality stem cells in a single…

Oncopeptides AB (Nasdaq Stockholm: ONCO) will today present follow-up data from the pivotal Phase 2 HORIZON (OP-106) study at the ASH Annual Meeting 2019. Melflufen showed an overall response rate (ORR) of 29% and clinical benefit rate (CBR) of 37% in patients with late-stage relapsed/refractory multiple myeloma (RRMM). The safety profile remained consistent with prior reports from the HORIZON study. These data reinforce Oncopeptides’ view that melflufen can play a role in the treatment of patients with RRMM and the Company plans to submit a New Drug Application (NDA) to the FDA in the first half of 2020. Overall Conclusions – HORIZON Poster Presentation…

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that results of the TOURMALINE-AL1 trial will be presented during an oral session at the 61st American Society of Hematology (ASH) annual meeting on Saturday, December 7, 2019 in Orlando, Florida. TOURMALINE-AL1 is a Phase 3, randomized clinical trial evaluating the effect of NINLAROTM (ixazomib) in combination with dexamethasone in patients with relapsed or refractory systemic light-chain (AL) amyloidosis. The TOURMALINE-AL1 trial did not meet the first of the two primary endpoints of significant improvement in overall hematologic response, as reported in June 2019. Hematologic responses were seen in 53% versus 51% of patients receiving…

The multi-center study met its primary endpoint with 53% of CIS ± Ta/T1 patients achieving a complete response (CR) at three months, and 24% continuing to show a CR at 12 months Additional data show 73% high-grade recurrence free (HGRF) survival in patients with papillary disease at three months and 44% HGRF survival at 12 months Clinical results also support a favorable safety and tolerability profile for nadofaragene firadenovec Nadofaragene firadenovec is administered intravesically once every three months December 05, 2019 04:30 PM Eastern Standard Time WASHINGTON–(BUSINESS WIRE)–FerGene, a new gene therapy company formed by Ferring Pharmaceuticals and Blackstone Life…

— The Leukemia & Lymphoma Society (LLS) and the American Society of Hematology (ASH) announced today a collaboration to expand access to LLS’s unique free service providing clinical trials navigation and support to blood cancer patients and their families. With only approximately five percent of adult cancer patients enrolling in clinical trials, this collaboration aims to bridge this gap and connect more blood cancer patients to appropriate clinical trials. “There are many obstacles preventing cancer patients from participating in clinical trials including accessibility, proximity and eligibility,” said Gwen Nichols, M.D., LLS chief medical officer. “Low participation in clinical trials can also be due to…

Joint FDA/ASH Led Initiative Highlights Importance of Using Patient Reported Outcomes and Biomarkers in Clinical Trials to Advance SCD Therapies  The American Society of Hematology (ASH) today released the most comprehensive set of recommendations to date aimed at establishing uniformity and global standards for clinical trial endpoints used to evaluate new therapies for sickle cell disease (SCD). The new recommendations – published in two companion papers in the current issue of Blood Advances – are the result of seven expert and patient led panels convened by ASH and the U.S. Food and Drug Administration (FDA) to improve the design of clinical trials for new SCD therapies, including promoting broader use of patient reported outcomes and biomarkers as clinical endpoints. Sickle…

Kymab, a clinical-stage biopharmaceutical company developing monoclonal and bispecific antibody-based therapeutics, today announced that abstracts describing two lead hematology programs, KY1049 and KY1066, will be presented at the American Society of Hematology 61st Annual Meeting and Exposition, being held December 7-10, 2019 in Orlando, Florida. The presentations will include posters highlighting preclinical data from these portfolio programs: KY1049 (a fully-human FVIII-mimetic common light chain bispecific antibody) and KY1066 (a fully-human antibody against matripase-2 for the treatment of iron overload in anemia). Poster presentation details are as follows: Title: 2410 - A Fully Human Bispecific Antibody Functionally Rescues Factor VIII Deficiency Ex Vivo Date &…

Partnership combines Caris’ somatic and Ambry’s germline testing strengths to provide clinicians with unique information about the molecular and genetic components of a patient’s cancer  Caris Life Sciences®, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, and Ambry Genetics (Ambry), a leading clinical genetic testing company, today announced that Caris will begin offering Ambry’s 67-gene CancerNext-Expanded panel to evaluate the hereditary risks for cancer. Combined with Caris’ somatic (tumor) tests that analyze a cancer’s detailed molecular makeup, Caris will provide patients and their healthcare providers unparalleled information to more accurately diagnose and treat cancer. This will be…

Rachel Brake @rachael_brake of Takeda discusses results from the phase 3 ALTA-1L trial and answers commonly asked questions regarding the results.

Atlanta Falcons and Atlanta United owner Arthur Blank’s gift is his second to Mount Sinai’s Department of Urology The Milton and Carroll Petrie Department of Urology at the Icahn School of Medicine at Mount Sinai has received a $1 million grant from The Arthur M. Blank Family Foundation.  This gift and a previous gift of $500,000 from The Arthur M. Blank Family Foundation will fund the Prostate Cancer Program at Mount Sinai, founded by Ash Tewari, MBBS, Chair of the Department of Urology at the Mount Sinai Health System and the Kyung Hyun Kim, MD Professor of Urology at the Icahn…

Meredith M. Regan,1 Michael B. Atkins,2 Thomas Powles,3 Lillian Werner,4 Charlene Mantia,5 Shuo Yang,6 Jennifer L. Johansen,6 Sumati Rao,6 Kyna M. Gooden,6 David F. McDermott7 1Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; 2Georgetown-Lombardi Comprehensive Cancer Center, Washington, DC; 3Barts Cancer Institute, Queen Mary University of London, Royal Free NHS Trust, London; 4Dana-Farber Cancer Institute, Boston, MA; 5Beth Israel Deaconess Medical Center, Boston, MA; 6Bristol-Myers Squibb, Princeton, NJ; 7Beth Israel Deaconess Medical Center, Dana-Farber/Harvard Cancer Center, Boston, MA Treatment-Free Survival, With and Without Toxicity, as a Novel Outcome Applied to Immuno-Oncology Agents in Advanced Renal Cell Carcinoma 18th International Kidney…

Chung-Han Lee1, Amishi Y. Shah2, Vicky Makker1, Matthew Taylor3, David Shaffer4, James J. Hsieh5, Allen L. Cohn6, Chris DiSimone7, Alvaro Pinto Marin8, Drew Rasco9, Sara Gunnestad Ribe10, Donald A. Richards11, Daniel E. Stepan*, Corina E. Dutcus12, Jane Wu12, Emmett V. Schmidt13, Rodolfo Perini13, Robert Motzer1 1Memorial Sloan Kettering Cancer Center, New York, NY, USA; 2MD Anderson Cancer Center, University of Texas, Houston, TX, USA; 3Oregon Health and Science University; Portland, OR, USA; 4New York Oncology Hematology, Albany, NY, USA; 5Washington University School of Medicine, St. Louis, MO, USA; 6Rocky Mountain Cancer Center, Denver, CO, USA; 7Arizona Oncology Associates, Tucson, AZ,…

Nicholas Vogelzang, MD of Comprehensive Cancer Centers discusses his moderation of modern imaging technology.

No evidence of cardiotoxicity to date; 40% of 10 patients dosed at ≥120 mg/m² demonstrate efficacy; trial progresses in Europe to 210 mg/m² Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced additional positive interim safety and efficacy data from one of the Company’s two ongoing open label, single arm Phase 1/2 studies of Annamycin for the treatment of relapsed or refractory acute myeloid leukemia (“AML”).  View press release online: https://www.prnewswire.com/news-releases/moleculin-announces-additional-positive-interim-results-from-phase-12-clinical-studies-of-annamycin-in-acute-myeloid-leukemia-300968855.html The Phase 1 portion of these clinical trials, which are described in more…

First metastatic triple-negative breast cancer patient showed no detectable circulating tumor cells (CTC) or putative metastatic tumor cells (EMTs) in the peripheral blood. Further, a significant reduction in CCR5 expression was demonstrated on cancer-associated cells after eight weeks of treatment with leronlimab A second patient with metastatic breast cancer has been enrolled under an emergency use investigational new drug VANCOUVER, Washington, Dec. 03, 2019 (GLOBE NEWSWIRE) – CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today additional early Phase 1b/2 clinical trial…

Nicholas Vogelzang, MD of Comprehensive Cancer Centers discusses his moderation of modern imaging technology.

Today, ASH published new state-of-the art guidelines on the treatment of immune thrombocytopenia (ITP), a rare blood disorder characterized by a decrease in the number of platelets, the part of the blood needed for normal clotting. The guidelines are published in the journal Blood Advances.  The 2019 ASH Clinical Practice Guidelines on ITP, developed in partnership with the University of Oklahoma Health Sciences Center, synthesize all available evidence about existing treatments to offer recommendations for disease management in both children and adults. Notably, these new guidelines address appropriate corticosteroid use in adults and stress avoiding unnecessary treatment in children. They also tackle the…

Ulka Vaishampayan, MD of @karmanoscancer explains her moderation of management for clinical cases in kidney cancer.

James Brugarolas, M.D., Ph.D. Director, Kidney Cancer Program Principal Investigator, Kidney Cancer SPORE Sherry Wigley Crow Endowed Chair in Cancer Research Professor of Internal Medicine / Hematology-Oncology Cancer Biology, Genetics, Development and Disease University of Texas Southwestern Medical Center discusses UT Southwestern Kidney Cancer Program & SPORE at the 18th International Kidney Cancer Symposium 2019, Miami, FL. _________ Presentation here: https://www.oncologytube.com/video/ut-southwestern-kidney-cancer-program-spore

A new collaborative study led by Cleveland Clinic and University Hospitals has found that commonly used clinical indicators of immune status and inflammation can predict mortality in the general population. Published in JAMA Network Open, the study showed that lymphopenia (a condition characterized by low levels of a specific type of white blood cell, called lymphocytes) is associated with death due to heart disease, cancer and respiratory infections, including influenza and pneumonia. This relationship between lymphocyte levels and mortality was observed independent of age, other blood-based immune markers and clinical risk factors.   The research team was led by David Zidar,…

Study results support development of LRIG1 as novel anti-cancer therapeutic Study is first to report that LRIG1 suppresses prostate cancer development LRIG1-derived peptide now being developed as anti-cancer therapeutic LRIG1 expression levels in tumors could become prognostic biomarker A research team led by a scientist at Roswell Park Comprehensive Cancer Center has identified the molecule LRIG1 as an important endogenous tumor suppressor in prostate cancer. Writing in the journal Nature Communications, the team documents their findings from preclinical studies showing that overexpression of the LRIG1 protein inhibits prostate cancer development, while reducing naturally occurring LRIG1 promotes prostate tumor development. Roswell…

Oluwadamilola “Lola” Fayanju, MD @DrLolaFayanju of @DukeCancer answers nodal response to neoadjuvant chemotherapy predicts receipt of radiation therapy: how can you be sure this is going to affect survival? ___________ Abstract: https://www.ncbi.nlm.nih.gov/pubmed/31678225

Oluwadamilola “Lola” Fayanju, MD @DrLolaFayanju of @DukeCancer explains the nodal response to neoadjuvant chemotherapy predicts receipt of radiation therapy after breast cancer diagnosis. __________ Abstract: https://www.ncbi.nlm.nih.gov/pubmed/31678225

Matt Campbell MD Assistant Professor GU Medical Oncology discusses The Argument for Front Line TKI based treatment for non-clear cell RCC at the 18th International Kidney Cancer Symposium 2019, Miami, FL. _________ Presentation here: https://www.oncologytube.com/video/the-argument-for-front-line-tki-based-treatment-for-non-clear-cell-rcc

Soricimed Biopharma Inc. (“Soricimed”), a clinical-stage pharmaceutical company developing first-in-class, targeted cancer therapeutics, today announced that a review of recent work on TRPV6 has been published in the peer-reviewed Journal of Cancer. The review identifies TRPV6 as a promising drug target in a number of cancers including breast, ovarian, prostate and pancreatic cancer. TRPV6 has emerged as a target in cancer treatment because of its role in increasing intracellular calcium and initiating downstream signalling pathways that increase cell proliferation, metastasis and inhibition of apoptosis (cell death). Soricimed’s lead drug candidate, SOR-C13, is a targeted inhibitor of TRPV6 that binds with high…

Viraj Master MD PhD FACS Professor Fray F. Marshall Chair in Urological Research Department of Urology Director of Integrative Oncology and Survivorship Winship Cancer Institute Emory University discusses Optimal Role of Consolidative Surgery in the IO Era at the 18th International Kidney Cancer Symposium 2019, Miami, FL. ____________ Presentation here: https://www.oncologytube.com/video/optimal-role-of-consolidative-surgery-in-the-io-era

ALUNBRIG Reduced the Risk of Disease Progression or Death by 76% in Patients whose Disease Had Spread to the Brain, and by 57% in All Patients, when Compared to Crizotinib  Median Progression-Free Survival with ALUNBRIG was Three Times Longer than that with Crizotinib – Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced updated data from the Phase 3 ALTA-1L trial, which evaluated ALUNBRIG versus crizotinib in adults with advanced anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) who had not received a prior ALK inhibitor. Results show after more than two years of follow-up, ALUNBRIG reduced the risk of disease progression or…

Alexander Kutikov, MD, FACS Professor and Chief, Urologic Oncology Fox Chase Cancer Center, Philadelphia, PA discusses Treatment of the Cystic Renal Mass: Gone Fishin’… for Minnows! at the 18th International Kidney Cancer Symposium 2019, Miami, FL. __________ Presentation here: https://www.oncologytube.com/video/treatment-of-the-cystic-renal-mass-gone-fishin-for-minnows-

Alexander Kutikov, MD, FACS Professor and Chief, Urologic Oncology Fox Chase Cancer Center, Philadelphia, PA discusses Treatment of the Cystic Renal Mass: Gone Fishin’… for Minnows! at the 18th International Kidney Cancer Symposium 2019, Miami, FL. _________ Presentation here: https://www.oncologytube.com/video/treatment-of-the-cystic-renal-mass-gone-fishin-for-minnows-

Marco Montillo, MD of @ospniguarda discusses the phase III DUO study. _________ https://investor.verastem.com/news-releases/news-release-details/verastem-oncology-announces-copiktratm-duvelisib-presentations-0 https://investor.verastem.com/news-releases/news-release-details/verastem-oncology-announces-copiktratm-duvelisib-presentations

Steven C. Campbell, MD, PhD Professor Surgery, Vice Chair, Program Director Section of Urologic Oncology, Department of Urology Glickman Urological and Kidney Institute Cleveland Clinic discusses Meaningful Endpoints for a Surgical Trial for Localized RCC at the 18th International Kidney Cancer Symposium 2019, Miami, FL. __________ Presentation here: https://www.oncologytube.com/video/meaningful-endpoints-for-a-surgical-trial-for-localized-rcc

Eytan Stein, MD of @sloan_kettering discusses the first patient dosed in phase 1/2 AUGMENT-101 trial of SNDX-5613 for the treatment with relapsed/refractory acute leukemias. __________ Syndax Pharmaceuticals, Inc. (“Syndax,” the “Company” or “we”) (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that the first patient has been dosed in AUGMENT-101, a Phase 1/2 clinical trial evaluating SNDX-5613, Syndax’s potent, highly selective oral Menin inhibitor, in patients with relapsed/refractory (R/R) acute leukemias.   “Dosing of the first patient in AUGMENT-101 represents an important milestone, both for the SNDX-5613 program and, importantly, for patients…

Pavlos Msaouel, MD, PhD Assistant Professor Genitourinary Medical Oncology The University of Texas MD Anderson Cancer Center discusses Changing Paradigms in Statistical Interpretation at the 18th International Kidney Cancer Symposium 2019, Miami, FL. ___________ Presentation here: https://www.oncologytube.com/video/changing-paradigms-in-statistical-interpretation

Ritesh Kotecha, Erika Gedvilaite, Samuel Murray, Ashley Foster, Robert Motzer, Dana Tsui, Martin Voss Memorial Sloan Kettering Cancer Center presents Circulating Tumor DNA (ctDNA) Results in 110 Patients with Advanced Clear Cell Renal Cell Carcinoma at the 18th International Kidney Cancer Symposium 2019, Miami, FL.

Preliminary results from phase 1 clinical trial of WP1220 for treatment of cutaneous T-cell lymphoma; supports phase 2 study — Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, announced it now has preliminary data from its clinical trial of WP1220 for the treatment of cutaneous T-cell lymphoma (“CTCL”), which was published in Blood in conjunction with the American Society of Hematology Annual Meeting and Exposition to be held December 7-10, 2019. View press release online: https://www.prnewswire.com/news-releases/moleculin-announces-positive-trial-data-with-100-safe-delivery-of-p-stat3-inhibitor-and-efficacy-in-majority-of-patients-300960607.html “For years, p-STAT3 (the activated form of STAT3) has been considered an…

Gabriela Chiosis of @sloan_kettering explains the importance of paradigms for precision medicine in cancer therapy. __________ Read here: https://www.cell.com/cancer-cell/fulltext/S1535-6108(19)30427-1#%20

Gabriela Chiosis, of @sloan_kettering discusses paradigms for precision medicine in epichaperome cancer therapy. _______ Read here: https://www.cell.com/cancer-cell/fulltext/S1535-6108(19)30427-1#%20 Also Recomended: Synthesis of 124I-labeled Epichaperome Probes

Primary efficacy endpoint met with 96.7% of men achieving sustained testosterone suppression to castrate levels (< 50 ng/dL) through 48 weeks Achieved all six key secondary endpoints, including superiority to leuprolide acetate on rapid suppression of testosterone and prostate-specific antigen (PSA), all with p-values < 0.0001 New Drug Application (NDA) submission expected in the second quarter of 2020 Conference call and webcast to be held today at 8:30 a.m. EST / 5:30 a.m. PST – Myovant Sciences (NYSE: MYOV), a healthcare company focused on developing innovative treatments for women’s health and prostate cancer, today announced that the Phase 3 HERO study of once-daily, oral relugolix…

Daniel M. Rotroff, PhD of @CleClinicMD answers will this affect clinicians and treatment today on anti-PD-1/PD-L1 antibody immunotherapy. _________ Read here: https://ascopubs.org/doi/full/10.1200/JCO.19.01712

Non-small-cell lung carcinoma (NSCLC) is an important area for the development and marketing of immuno-oncology (IO) drugs for most large pharmaceutical companies in space, both as monotherapy and in conjunction with other IO agents. The market and use of IO therapies in NSCLC for targeted therapies and chemotherapies is expected to continue to grow, and IO therapies will account for more than 50%.  Tajekesa Chapman, Senior Oncology and Hematology Analyst at GlobalData, comments: “AstraZeneca recently announced that its combination of Imfinzi (durvalumab) + chemotherapy, with or without tremelimumab, met its key endpoint of improving progression-free survival (PFS) when compared to…

Daniel M. Rotroff, PhD of @CleClinicMD answers commonly asked questions to anti-PD-1/PD-L1 antibody immunotherapy. _________ Read here: https://ascopubs.org/doi/full/10.1200/JCO.19.01712

Daniel M. Rotroff, PhD of @CleClinicMD discusses the response to anti-PD-1/PD-L1 antibody immunotherapy. __________ Read here: https://ascopubs.org/doi/full/10.1200/JCO.19.01712

    Philadelphia, PA (November 20, 2019) – Oncoceutics, Inc. announced that new  data will be presented  on the efficacy and mechanism of action of  imipridones ONC201 and ONC206 at the 24th Annual Scientific Meeting of the Society of Neuro-Oncology, to be held November 20th-24th in Phoenix, Arizona. These data will highlight exciting findings that have emerged over the past year, including: ·       Updated clinical results for ONC201 in pediatric and adult H3 K27M-mutant gliomas ·       Extension of ONC201 activity to other brain tumors ·       Synergy antitumor activity of ONC201 in combination with other treatments ·       Activity of ONC206 in…

Craig Slingluff, MD of @UVACancerCenter answers the study design and what is next for phase III data for a melanoma vaccine, seviprotimut-L. _____________ — MAVIS Study Identifies Most Responsive Patient Subpopulations, Supporting the Continued Study of Adjuvant Treatment in Localized Melanoma Patients — Polynoma LLC, a U.S. immuno-oncology focused biopharmaceutical company and wholly-owned subsidiary of Hong Kong-listed CK Life Sciences Int’l., (Holdings) Inc., is presenting clinical data from MAVIS (Melanoma Antigen Vaccine Immunotherapy Study), its ongoing Phase III clinical study of seviprotimut-L, an investigational melanoma vaccine candidate, on November 8 at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting…

Philadelphia, PA (Nov. 19, 2019) – Oncoceutics, Inc. announced a publication in the journal Nature Communications demonstrating selective antagonism of the G-protein coupled receptor (GPCR) dopamine receptor D2 (DRD2) by Oncoceutics’ lead candidate imipridone, ONC201.ONC201 was found to specifically bind and antagonize DRD2, and its functionally redundant family member DRD3, without affecting other dopamine receptors, other GPCRs, nuclear hormone receptors, kinases, or other drug targets of FDA-approved cancer therapies. Additionally, a biologically inactive isomer of ONC201 did not antagonize DRD2, indicating that antagonism of this receptor may be linked to anti-cancer efficacy as shown in other publications (Clinical Cancer Research…

Philadelphia, PA (November 13, 2019) – Oncoceutics, Inc. announced that results from the second and third cohort of the Phase II trial for patients with recurrent glioblastoma treated with the company’s lead imipridone, ONC201, were recently published in the journal Neuro-Oncology. This manuscript represents the third publication among a series of reports demonstrating durable radiographic regressions with ONC201 in patients with H3 K27M-mutant glioma. The study (NCT02525692) also demonstrated that weekly oral administration of ONC201 given as a single agent was well-tolerated, achieved therapeutic intratumoral concentrations, and intratumoral pharmacodynamic activity in adult recurrent glioblastoma patients. ONC201 achieved intratumoral concentrations that exceeded…

Bryan Lewis, President KidneyCan discusses An Advocates Perspective to Increasing Funding Resources at the 18th International Kidney Cancer Symposium 2019, Miami, FL.

Craig Slingluff, MD of @UVACancerCenter discusses the phase III data for a melanoma vaccine, seviprotimut-L. ____________ — MAVIS Study Identifies Most Responsive Patient Subpopulations, Supporting the Continued Study of Adjuvant Treatment in Localized Melanoma Patients — Polynoma LLC, a U.S. immuno-oncology focused biopharmaceutical company and wholly-owned subsidiary of Hong Kong-listed CK Life Sciences Int’l., (Holdings) Inc., is presenting clinical data from MAVIS (Melanoma Antigen Vaccine Immunotherapy Study), its ongoing Phase III clinical study of seviprotimut-L, an investigational melanoma vaccine candidate, on November 8 at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting in National Harbor, Maryland. MAVIS is an adaptive phase III multicenter, double-blind, placebo-controlled trial to assess the safety and efficacy of seviprotimut-L, with primary endpoints of recurrence-free survival (RFS) and overall survival (OS) in patients with American Joint Cancer Committee (AJCC) Stage IIB / C, IIIA, IIIB / C melanoma at high risk of recurrence following definitive surgical resection. Highlights of…

Patients show improvements in blood vessels and physical ability after 8-week regimen — While exercise offers benefits for a wide range of health conditions, it has historically been considered too dangerous for people living with sickle cell disease (SCD). However, a new study published today in the journal Blood adds to mounting evidence that low-to moderate-intensity exercise may be not only safe, but beneficial for these patients. SCD affects how blood flows through the body. For those with SCD, strenuous physical activity increases blood flow and can lead to serious complications including heart problems and episodes of severe pain known as vaso-occlusive crises. While many…

Christopher Wood, MD from MDAnderson holds a kidney cancer tumor board with real cases from the Kidney Cancer Association annual meeting in Miami, FL 2019

Hans Hammers MD, PhD presents Radiation to Prime the Immune System Filmed at the 18th International Kidney Cancer Symposium 2019, Miami, FL.

Neal Shore, MD of Carolina Urologic Research Center @UrologyUS on how the ProVent trial might change the AS treatment landscape. ________ Dendreon Pharmaceuticals, a commercial-stage biopharmaceutical company and pioneer in the development of immunotherapy, announced early completion of patient enrollment of its Phase 3 ProVent clinical trial. More than 450 subjects were randomized in the large-scale clinical trial, which is evaluating the effectiveness of sipuleucel-T (PROVENGE®) in reducing disease progression in men with early-stage prostate cancer on active surveillance (AS). “The rapid pace of enrollment in the ProVent trial is a significant milestone for Dendreon, and underscores a strong interest…

Neal Shore, MD of Carolina Urologic Research Center @UrologyUS on how the ProVent trial might change the AS treatment landscape. _________ Dendreon Pharmaceuticals, a commercial-stage biopharmaceutical company and pioneer in the development of immunotherapy, announced early completion of patient enrollment of its Phase 3 ProVent clinical trial. More than 450 subjects were randomized in the large-scale clinical trial, which is evaluating the effectiveness of sipuleucel-T (PROVENGE®) in reducing disease progression in men with early-stage prostate cancer on active surveillance (AS). “The rapid pace of enrollment in the ProVent trial is a significant milestone for Dendreon, and underscores a strong interest…

Neal Shore, MD of Carolina Urologic Research Center @UrologyUS on how the ProVent trial might change the AS treatment landscape. __________ Dendreon Pharmaceuticals, a commercial-stage biopharmaceutical company and pioneer in the development of immunotherapy, announced early completion of patient enrollment of its Phase 3 ProVent clinical trial. More than 450 subjects were randomized in the large-scale clinical trial, which is evaluating the effectiveness of sipuleucel-T (PROVENGE®) in reducing disease progression in men with early-stage prostate cancer on active surveillance (AS). “The rapid pace of enrollment in the ProVent trial is a significant milestone for Dendreon, and underscores a strong interest…

Neal Shore, MD of Carolina Urologic Research Center @UrologyUS provides insight on current treatment options for men in the phase 3 provent trial. __________ Dendreon Pharmaceuticals, a commercial-stage biopharmaceutical company and pioneer in the development of immunotherapy, announced early completion of patient enrollment of its Phase 3 ProVent clinical trial. More than 450 subjects were randomized in the large-scale clinical trial, which is evaluating the effectiveness of sipuleucel-T (PROVENGE®) in reducing disease progression in men with early-stage prostate cancer on active surveillance (AS). “The rapid pace of enrollment in the ProVent trial is a significant milestone for Dendreon, and underscores…

Neal Shore, MD of Carolina Urologic Research Center @UrologyUS discusses the phase 3 provent clinical trial. ____________ Dendreon Pharmaceuticals, a commercial-stage biopharmaceutical company and pioneer in the development of immunotherapy, announced early completion of patient enrollment of its Phase 3 ProVent clinical trial. More than 450 subjects were randomized in the large-scale clinical trial, which is evaluating the effectiveness of sipuleucel-T (PROVENGE®) in reducing disease progression in men with early-stage prostate cancer on active surveillance (AS). “The rapid pace of enrollment in the ProVent trial is a significant milestone for Dendreon, and underscores a strong interest by patients and physicians…

Robert Hapke, Katherine E. Beckermann MD/PhD, W. Kimryn Rathmell MD/PhD, and Scott M. Haake MD Vanderbilt-Ingram Cancer Center Vanderbilt University Medical Center presents Loss of SETD2 is associated with dysregulation of protein translation in clear cell renal cell carcinoma. Filmed at the 18th International Kidney Cancer Symposium 2019, Miami, FL.

Abhishek Tripathi MD Assistant Professor, Section of Hematology Oncology University of Oklahoma Stephenson Cancer Center Oklahoma City, OK presents Immune Correlates and Prognostic Significance of CD73 Expression in Renal Cell Carcinoma Filmed at the 18th International Kidney Cancer Symposium 2019, Miami, FL.

Leigh Ellis Department of Oncologic Pathology Dana-Farber Cancer Institute Harvard Medical School presents Using Epigenetic Therapy to Enhance Immunotherapy Response in RCC Filmed at the 18th International Kidney Cancer Symposium 2019, Miami, FL.

Thai Ho Mayo Clinic Arizona presents Therapeutic targeting of the extracellular matrix in kidney cancer Filmed at the 18th International Kidney Cancer Symposium 2019, Miami, FL.

Charles G. Drake MD / PhD Director GU Medical Oncology Co-Director: Immunotherapy Program Associate Director for Clinical Research Professor of Oncology and Urology Herbert Irving Cancer Center at Columbia University presents Innate Cytokines and Myeloid Cells Filmed at the 18th International Kidney Cancer Symposium 2019, Miami, FL.

Aguirre A. de Cubas, Ph.D. Post-Doctoral Fellow WK Rathmell Lab Vanderbilt University Medical School presents DNA Demethylation promotes ERV expression and activation of immune signaling in renal cell cancer cells Filmed at the 18th International Kidney Cancer Symposium 2019, Miami, FL.

Haydn Kissick, Ph.D. Department of UrologyDepartment of Microbiology and Immunology presents The T-cell response to Kidney Cancer Filmed at the 18th International Kidney Cancer Symposium 2019, Miami, FL.

Arlene Sharpe M.D. Ph.D. Department of Immunology Harvard Medical School presents Discovery of new IO Targets Leveraging CRISPR Filmed at the 18th International Kidney Cancer Symposium 2019, Miami, FL.

Patient-reported ECOG performance status (PS) is lower than oncologist-reported PS and is associated with worse psychosocial outcomes. Cristiane Decat Bergerot, PhD Psychologist, Postdoctoral Fellow City of Hope Comprehensive Cancer Center And colleagues Paulo Bergerot, MD; Errol Philip, PhD; JoAnn Hsu, BS; Nazli Dizman, MD; Meghan Salgia; Dena Battle; Ulka Vaishampayan, MD; Matthew Loscalzo, LCSW; William Dale, MD, PhD; Sumanta K. Pal, MD Filmed at the 18th International Kidney Cancer Symposium 2019, Miami, FL.     cancer research, toxicity and response criteria of the eastern cooperative oncology group ecog About ECOG Performance Status: To conduct clinical cancer treatment trials effectively across…

Meredith M. Regan,1 Michael B. Atkins,2 Thomas Powles,3 Lillian Werner,4 Charlene Mantia,5 Shuo Yang,6 Jennifer L. Johansen,6 Sumati Rao,6 Kyna M. Gooden,6 David F. McDermott7 1Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; 2Georgetown-Lombardi Comprehensive Cancer Center, Washington, DC; 3Barts Cancer Institute, Queen Mary University of London, Royal Free NHS Trust, London; 4Dana-Farber Cancer Institute, Boston, MA; 5Beth Israel Deaconess Medical Center, Boston, MA; 6Bristol-Myers Squibb, Princeton, NJ; 7Beth Israel Deaconess Medical Center, Dana-Farber/Harvard Cancer Center, Boston, MA Treatment-Free Survival, With and Without Toxicity, as a Novel Outcome Applied to Immuno-Oncology Agents in Advanced Renal Cell Carcinoma 18th International Kidney…

Chung-Han Lee1, Amishi Y. Shah2, Vicky Makker1, Matthew Taylor3, David Shaffer4, James J. Hsieh5, Allen L. Cohn6, Chris DiSimone7, Alvaro Pinto Marin8, Drew Rasco9, Sara Gunnestad Ribe10, Donald A. Richards11, Daniel E. Stepan*, Corina E. Dutcus12, Jane Wu12, Emmett V. Schmidt13, Rodolfo Perini13, Robert Motzer1 1Memorial Sloan Kettering Cancer Center, New York, NY, USA; 2MD Anderson Cancer Center, University of Texas, Houston, TX, USA; 3Oregon Health and Science University; Portland, OR, USA; 4New York Oncology Hematology, Albany, NY, USA; 5Washington University School of Medicine, St. Louis, MO, USA; 6Rocky Mountain Cancer Center, Denver, CO, USA; 7Arizona Oncology Associates, Tucson, AZ,…